Literature DB >> 7827347

Current therapeutic management of diabetic nephropathy.

S M Kohler1, B K Krämer.   

Abstract

Roughly 40% of all patients with insulin-dependent diabetes mellitus (IDDM) develop diabetic nephropathy with proteinuria, hypertension and a decrease in glomerular filtration rate 10 to 20 years after the onset of the disease, and 5 years later most patients suffer from end-stage renal disease. Microalbuminuria, defined as an urinary albumin excretion rate (UAER) between 30 and 300 mg/day, strongly predicts the development of nephropathy in IDDM. Nearly all patients with IDDM, a decreasing glomerular filtration rate and a UAER > 300 mg/day have coexisting hypertensive disease additionally worsening renal function. We review the results of recent long-term studies of the current therapeutic management in diabetic patients by means of better blood pressure control, low-protein diet and near-normal blood glucose control in the early microalbuminuric phase as well as in the later phases of the disease characterized by diabetic nephropathy with a UAER > 300 mg/day. Since the large majority of studies have been performed on IDDM, our conclusions with regard to therapy are only valid in this subgroup of diabetic patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7827347     DOI: 10.1007/bf00570363

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  46 in total

1.  Effects of a selective thromboxane synthetase inhibitor OKY-046 on experimental diabetic nephropathy.

Authors:  K Hora; H Oguchi; T Furukawa; K Hora; S Tokunaga
Journal:  Nephron       Date:  1990       Impact factor: 2.847

2.  Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies.

Authors:  B Feldt-Rasmussen; E R Mathiesen; T Jensen; T Lauritzen; T Deckert
Journal:  Diabetologia       Date:  1991-03       Impact factor: 10.122

Review 3.  Microalbuminuria as a predictor of clinical diabetic nephropathy.

Authors:  C E Mogensen
Journal:  Kidney Int       Date:  1987-02       Impact factor: 10.612

4.  Nephropathy is delayed by intensified insulin treatment in patients with insulin-dependent diabetes mellitus and retinopathy.

Authors:  P Reichard; U Rosenqvist
Journal:  J Intern Med       Date:  1989-08       Impact factor: 8.989

Review 5.  [Diabetic nephropathy. Pathogenetic, diagnostic and therapeutic concepts].

Authors:  W Kleophas; T Voitz; H Messner; F A Gries
Journal:  Fortschr Med       Date:  1990-05-30

6.  Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.

Authors:  R Zatz; B R Dunn; T W Meyer; S Anderson; H G Rennke; B M Brenner
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

7.  Effects of ACE inhibition supplementary to beta blockers and diuretics in early diabetic nephropathy.

Authors:  M M Pedersen; K W Hansen; A Schmitz; K Sørensen; C K Christensen; C E Mogensen
Journal:  Kidney Int       Date:  1992-04       Impact factor: 10.612

Review 8.  Diabetic nephropathy: a disease causing and complicated by hypertension.

Authors:  M W Steffes; S M Mauer
Journal:  Clin Chem       Date:  1991-10       Impact factor: 8.327

9.  Long-term glycemic control and kidney function in insulin-dependent diabetes mellitus.

Authors:  K Dahl-Jørgensen; T Bjøro; P Kierulf; L Sandvik; H J Bangstad; K F Hanssen
Journal:  Kidney Int       Date:  1992-04       Impact factor: 10.612

10.  Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy.

Authors:  C E Mogensen
Journal:  Br Med J (Clin Res Ed)       Date:  1982-09-11
View more
  1 in total

1.  Antidiabetic activities of polysaccharides separated from Inonotus obliquus via the modulation of oxidative stress in mice with streptozotocin-induced diabetes.

Authors:  Juan Wang; Wenji Hu; Lanzhou Li; Xinping Huang; Yange Liu; Di Wang; Lirong Teng
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.